 Ilango Balakrishnan
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 6 | 2022 | 172 | 0.720 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 38 | 0.690 |
Why?
| | Cerebellar Neoplasms | 5 | 2022 | 130 | 0.640 |
Why?
| | Glioma | 4 | 2022 | 284 | 0.540 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 262 | 0.500 |
Why?
| | MicroRNAs | 3 | 2014 | 598 | 0.420 |
Why?
| | Genome, Human | 2 | 2014 | 342 | 0.410 |
Why?
| | Cell Cycle Proteins | 5 | 2022 | 543 | 0.380 |
Why?
| | Aging | 1 | 2020 | 1601 | 0.360 |
Why?
| | Cell Line, Tumor | 10 | 2022 | 2690 | 0.340 |
Why?
| | Cell Proliferation | 7 | 2022 | 2164 | 0.300 |
Why?
| | Nuclear Proteins | 3 | 2017 | 584 | 0.270 |
Why?
| | Histones | 2 | 2020 | 528 | 0.250 |
Why?
| | Proto-Oncogene Proteins | 3 | 2022 | 595 | 0.230 |
Why?
| | Pyrazoles | 4 | 2022 | 361 | 0.230 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 390 | 0.220 |
Why?
| | Epigenomics | 2 | 2020 | 98 | 0.210 |
Why?
| | Genes, myc | 2 | 2020 | 44 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2022 | 1872 | 0.200 |
Why?
| | Stromal Cells | 2 | 2014 | 95 | 0.200 |
Why?
| | Pyrimidinones | 2 | 2020 | 88 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 55 | 0.190 |
Why?
| | Radiation Tolerance | 1 | 2022 | 91 | 0.190 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 80 | 0.180 |
Why?
| | Chromatin | 2 | 2020 | 418 | 0.170 |
Why?
| | Down-Regulation | 2 | 2014 | 593 | 0.170 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 31 | 0.170 |
Why?
| | Astrocytoma | 1 | 2020 | 106 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2020 | 1140 | 0.170 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 84 | 0.170 |
Why?
| | Deoxycytidine | 1 | 2020 | 137 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 848 | 0.160 |
Why?
| | Lysine | 1 | 2020 | 240 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 443 | 0.150 |
Why?
| | RNA, Messenger | 3 | 2014 | 2507 | 0.150 |
Why?
| | Argonaute Proteins | 2 | 2014 | 28 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2017 | 272 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.130 |
Why?
| | Pteridines | 1 | 2016 | 20 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 37 | 0.130 |
Why?
| | Apoptosis | 6 | 2022 | 2288 | 0.130 |
Why?
| | Ependymoma | 1 | 2017 | 152 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 283 | 0.120 |
Why?
| | Jagged-1 Protein | 1 | 2014 | 22 | 0.110 |
Why?
| | Serrate-Jagged Proteins | 1 | 2014 | 27 | 0.110 |
Why?
| | Wnt-5a Protein | 1 | 2014 | 18 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2014 | 435 | 0.110 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2014 | 55 | 0.110 |
Why?
| | NF-kappa B | 1 | 2017 | 615 | 0.110 |
Why?
| | Immunoprecipitation | 1 | 2014 | 150 | 0.110 |
Why?
| | Cell Differentiation | 1 | 2020 | 1681 | 0.110 |
Why?
| | Cellular Microenvironment | 1 | 2014 | 75 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 115 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2016 | 1029 | 0.110 |
Why?
| | Wnt Proteins | 1 | 2014 | 124 | 0.100 |
Why?
| | Brain Neoplasms | 2 | 2020 | 964 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 201 | 0.100 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 344 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 345 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 496 | 0.090 |
Why?
| | Cell Line | 2 | 2014 | 2581 | 0.090 |
Why?
| | Cerebellum | 1 | 2012 | 196 | 0.090 |
Why?
| | Child, Preschool | 3 | 2020 | 9093 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 326 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2010 | 74 | 0.090 |
Why?
| | Mutation | 1 | 2020 | 3313 | 0.090 |
Why?
| | Base Sequence | 1 | 2014 | 2080 | 0.090 |
Why?
| | Humans | 14 | 2022 | 113531 | 0.080 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2741 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2014 | 677 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2014 | 1008 | 0.070 |
Why?
| | Child | 3 | 2022 | 18340 | 0.070 |
Why?
| | Transcription Factors | 1 | 2014 | 1497 | 0.070 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 515 | 0.060 |
Why?
| | Cell Survival | 2 | 2016 | 1004 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 739 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 71 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2010 | 2293 | 0.050 |
Why?
| | Cell Cycle | 2 | 2014 | 538 | 0.050 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 129 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 207 | 0.050 |
Why?
| | Teratoma | 1 | 2022 | 92 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 173 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 239 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 516 | 0.040 |
Why?
| | Piperazines | 1 | 2022 | 309 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 442 | 0.040 |
Why?
| | Female | 2 | 2020 | 59115 | 0.040 |
Why?
| | Prognosis | 2 | 2016 | 3318 | 0.040 |
Why?
| | Mice | 3 | 2022 | 14679 | 0.030 |
Why?
| | Animals | 4 | 2022 | 31162 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 737 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| | Urea | 1 | 2016 | 65 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 331 | 0.030 |
Why?
| | Male | 1 | 2020 | 55112 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 261 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 1925 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 617 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 345 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 809 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 69 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 716 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 794 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1110 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 310 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 123 | 0.030 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.030 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.030 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2012 | 37 | 0.030 |
Why?
| | Mice, Nude | 1 | 2014 | 625 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 834 | 0.030 |
Why?
| | Colorado | 1 | 2022 | 4061 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 914 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 693 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1128 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 112 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 435 | 0.020 |
Why?
| | Pyrimidines | 1 | 2014 | 372 | 0.020 |
Why?
| | CD146 Antigen | 1 | 2010 | 35 | 0.020 |
Why?
| | Chemotaxis | 1 | 2010 | 128 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1634 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2010 | 170 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 358 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 288 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 625 | 0.020 |
Why?
| | Ligands | 1 | 2010 | 553 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2012 | 685 | 0.020 |
Why?
| | Brain | 1 | 2020 | 2309 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1356 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 852 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 779 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1510 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 1065 | 0.020 |
Why?
| | Fibroblasts | 1 | 2010 | 827 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2754 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 4439 | 0.010 |
Why?
|
|
Balakrishnan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|